|
Gene: CTSL |
Gene summary for CTSL |
Gene summary. |
Gene information | Species | Human | Gene symbol | CTSL | Gene ID | 1514 |
Gene name | cathepsin L | |
Gene Alias | CATL | |
Cytomap | 9q21.33 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | A0A024R276 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1514 | CTSL | AEH-subject1 | Human | Endometrium | AEH | 4.79e-03 | -1.85e-01 | -0.3059 |
1514 | CTSL | AEH-subject2 | Human | Endometrium | AEH | 4.71e-02 | -1.72e-01 | -0.2525 |
1514 | CTSL | AEH-subject5 | Human | Endometrium | AEH | 4.58e-06 | -2.75e-01 | -0.2953 |
1514 | CTSL | EEC-subject1 | Human | Endometrium | EEC | 3.06e-06 | -2.28e-01 | -0.2682 |
1514 | CTSL | EEC-subject2 | Human | Endometrium | EEC | 1.02e-07 | -2.21e-01 | -0.2607 |
1514 | CTSL | EEC-subject3 | Human | Endometrium | EEC | 1.48e-29 | -2.28e-01 | -0.2525 |
1514 | CTSL | EEC-subject4 | Human | Endometrium | EEC | 6.26e-04 | -1.14e-01 | -0.2571 |
1514 | CTSL | EEC-subject5 | Human | Endometrium | EEC | 3.98e-02 | -8.70e-02 | -0.249 |
1514 | CTSL | GSM5276934 | Human | Endometrium | EEC | 1.12e-24 | 7.89e-01 | -0.0913 |
1514 | CTSL | GSM5276937 | Human | Endometrium | EEC | 2.93e-38 | 1.07e+00 | -0.0897 |
1514 | CTSL | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.75e-11 | -9.39e-02 | -0.1869 |
1514 | CTSL | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 6.18e-10 | -2.59e-01 | -0.1875 |
1514 | CTSL | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.30e-12 | -2.11e-01 | -0.1883 |
1514 | CTSL | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 6.68e-18 | -1.99e-01 | -0.1934 |
1514 | CTSL | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 9.67e-26 | -2.75e-01 | -0.1917 |
1514 | CTSL | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.69e-11 | -2.48e-01 | -0.1916 |
1514 | CTSL | LZE2T | Human | Esophagus | ESCC | 2.61e-07 | 6.09e-01 | 0.082 |
1514 | CTSL | LZE4T | Human | Esophagus | ESCC | 2.01e-13 | 2.43e-01 | 0.0811 |
1514 | CTSL | LZE6T | Human | Esophagus | ESCC | 1.10e-07 | 1.08e+00 | 0.0845 |
1514 | CTSL | P2T-E | Human | Esophagus | ESCC | 1.24e-15 | 3.13e-01 | 0.1177 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603216 | Endometrium | AEH | viral process | 110/2100 | 415/18723 | 1.99e-18 | 1.09e-15 | 110 |
GO:001905816 | Endometrium | AEH | viral life cycle | 86/2100 | 317/18723 | 2.53e-15 | 7.58e-13 | 86 |
GO:004440316 | Endometrium | AEH | biological process involved in symbiotic interaction | 70/2100 | 290/18723 | 3.26e-10 | 3.55e-08 | 70 |
GO:005170116 | Endometrium | AEH | biological process involved in interaction with host | 53/2100 | 203/18723 | 2.48e-09 | 1.93e-07 | 53 |
GO:005212616 | Endometrium | AEH | movement in host environment | 46/2100 | 175/18723 | 2.20e-08 | 1.31e-06 | 46 |
GO:004671816 | Endometrium | AEH | viral entry into host cell | 37/2100 | 144/18723 | 9.32e-07 | 3.24e-05 | 37 |
GO:004440916 | Endometrium | AEH | entry into host | 38/2100 | 151/18723 | 1.17e-06 | 3.82e-05 | 38 |
GO:001988415 | Endometrium | AEH | antigen processing and presentation of exogenous antigen | 16/2100 | 47/18723 | 2.96e-05 | 5.47e-04 | 16 |
GO:000247815 | Endometrium | AEH | antigen processing and presentation of exogenous peptide antigen | 14/2100 | 38/18723 | 3.38e-05 | 6.05e-04 | 14 |
GO:00068988 | Endometrium | AEH | receptor-mediated endocytosis | 49/2100 | 244/18723 | 3.54e-05 | 6.24e-04 | 49 |
GO:001988610 | Endometrium | AEH | antigen processing and presentation of exogenous peptide antigen via MHC class II | 12/2100 | 30/18723 | 4.77e-05 | 7.88e-04 | 12 |
GO:00421109 | Endometrium | AEH | T cell activation | 81/2100 | 487/18723 | 1.78e-04 | 2.30e-03 | 81 |
GO:00024959 | Endometrium | AEH | antigen processing and presentation of peptide antigen via MHC class II | 12/2100 | 34/18723 | 1.97e-04 | 2.49e-03 | 12 |
GO:004800215 | Endometrium | AEH | antigen processing and presentation of peptide antigen | 17/2100 | 62/18723 | 3.46e-04 | 3.80e-03 | 17 |
GO:00025049 | Endometrium | AEH | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 12/2100 | 36/18723 | 3.63e-04 | 3.96e-03 | 12 |
GO:00447642 | Endometrium | AEH | multi-organism cellular process | 7/2100 | 14/18723 | 3.71e-04 | 4.02e-03 | 7 |
GO:001988216 | Endometrium | AEH | antigen processing and presentation | 23/2100 | 106/18723 | 1.36e-03 | 1.15e-02 | 23 |
GO:00447663 | Endometrium | AEH | multi-organism transport | 7/2100 | 21/18723 | 6.20e-03 | 3.70e-02 | 7 |
GO:19025793 | Endometrium | AEH | multi-organism localization | 7/2100 | 21/18723 | 6.20e-03 | 3.70e-02 | 7 |
GO:001603217 | Endometrium | EEC | viral process | 112/2168 | 415/18723 | 2.48e-18 | 1.35e-15 | 112 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541826 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0461225 | Endometrium | AEH | Antigen processing and presentation | 26/1197 | 78/8465 | 1.33e-05 | 1.55e-04 | 1.13e-04 | 26 |
hsa0414524 | Endometrium | AEH | Phagosome | 41/1197 | 152/8465 | 2.12e-05 | 2.22e-04 | 1.63e-04 | 41 |
hsa0532316 | Endometrium | AEH | Rheumatoid arthritis | 23/1197 | 93/8465 | 4.43e-03 | 2.46e-02 | 1.80e-02 | 23 |
hsa0421010 | Endometrium | AEH | Apoptosis | 30/1197 | 136/8465 | 7.72e-03 | 4.05e-02 | 2.96e-02 | 30 |
hsa05418112 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa04612111 | Endometrium | AEH | Antigen processing and presentation | 26/1197 | 78/8465 | 1.33e-05 | 1.55e-04 | 1.13e-04 | 26 |
hsa04145111 | Endometrium | AEH | Phagosome | 41/1197 | 152/8465 | 2.12e-05 | 2.22e-04 | 1.63e-04 | 41 |
hsa0532317 | Endometrium | AEH | Rheumatoid arthritis | 23/1197 | 93/8465 | 4.43e-03 | 2.46e-02 | 1.80e-02 | 23 |
hsa0421015 | Endometrium | AEH | Apoptosis | 30/1197 | 136/8465 | 7.72e-03 | 4.05e-02 | 2.96e-02 | 30 |
hsa0541827 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
hsa0461226 | Endometrium | EEC | Antigen processing and presentation | 27/1237 | 78/8465 | 7.66e-06 | 9.58e-05 | 7.14e-05 | 27 |
hsa0414525 | Endometrium | EEC | Phagosome | 42/1237 | 152/8465 | 2.01e-05 | 2.28e-04 | 1.70e-04 | 42 |
hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa0532323 | Endometrium | EEC | Rheumatoid arthritis | 24/1237 | 93/8465 | 3.14e-03 | 1.78e-02 | 1.33e-02 | 24 |
hsa0421024 | Endometrium | EEC | Apoptosis | 31/1237 | 136/8465 | 6.72e-03 | 3.25e-02 | 2.42e-02 | 31 |
hsa0541836 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
hsa0461235 | Endometrium | EEC | Antigen processing and presentation | 27/1237 | 78/8465 | 7.66e-06 | 9.58e-05 | 7.14e-05 | 27 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTSL | SNV | Missense_Mutation | novel | c.774N>A | p.Phe258Leu | p.F258L | P07711 | protein_coding | tolerated(0.21) | possibly_damaging(0.686) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CTSL | SNV | Missense_Mutation | novel | c.293N>A | p.Arg98His | p.R98H | P07711 | protein_coding | tolerated(0.11) | benign(0.121) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTSL | SNV | Missense_Mutation | c.410N>A | p.Ser137Tyr | p.S137Y | P07711 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
CTSL | SNV | Missense_Mutation | c.938N>C | p.Lys313Thr | p.K313T | P07711 | protein_coding | deleterious(0.04) | probably_damaging(0.955) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CTSL | SNV | Missense_Mutation | rs759124688 | c.101C>T | p.Ala34Val | p.A34V | P07711 | protein_coding | tolerated(0.27) | benign(0.009) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTSL | SNV | Missense_Mutation | novel | c.685C>T | p.Pro229Ser | p.P229S | P07711 | protein_coding | tolerated(0.08) | benign(0.358) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTSL | SNV | Missense_Mutation | novel | c.935T>C | p.Val312Ala | p.V312A | P07711 | protein_coding | deleterious(0) | benign(0.367) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTSL | SNV | Missense_Mutation | c.584N>A | p.Gly195Asp | p.G195D | P07711 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BS-A0TJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CTSL | SNV | Missense_Mutation | c.162N>T | p.Lys54Asn | p.K54N | P07711 | protein_coding | tolerated(0.13) | benign(0.229) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CTSL | SNV | Missense_Mutation | c.549N>A | p.Met183Ile | p.M183I | P07711 | protein_coding | deleterious(0.03) | benign(0.107) | TCGA-D1-A16Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1514 | CTSL | PROTEASE, DRUGGABLE GENOME, ENZYME | PMID27998201-Compound-6 | |||
1514 | CTSL | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 405067337 | ||
1514 | CTSL | PROTEASE, DRUGGABLE GENOME, ENZYME | HORMONES | 16099855 | ||
1514 | CTSL | PROTEASE, DRUGGABLE GENOME, ENZYME | PMID27998201-Compound-19 | |||
1514 | CTSL | PROTEASE, DRUGGABLE GENOME, ENZYME | KGP94 | |||
1514 | CTSL | PROTEASE, DRUGGABLE GENOME, ENZYME | PMID27998201-Compound-5 | |||
1514 | CTSL | PROTEASE, DRUGGABLE GENOME, ENZYME | Phenylalanine derivative 1 | |||
1514 | CTSL | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 318164817 | ||
1514 | CTSL | PROTEASE, DRUGGABLE GENOME, ENZYME | PMID27998201-Compound-1 | |||
1514 | CTSL | PROTEASE, DRUGGABLE GENOME, ENZYME | PMID27998201-Compound-9 |
Page: 1 2 |